RELATED: Merck seeks FDA authorization of antiviral COVID-19 pillCharles Gore, the executive director of the Medicines Patent Pool, said the early results for molnupiravir were "compelling" and that he hoped this first voluntary licensing agreement for a COVID-19 treatment would lead to others.Despite repeated requests from governments and health officials, no vaccine makers have agreed to a similar deal.
A hub set up by WHO in South Africa intended to share messenger RNA vaccine recipes and technologies has not enticed a single pharmaceutical to join.FILE IMAGE - Merck & Co.
logo displayed on a laptop screen and medical pills are seen in this illustration photo taken in Krakow, Poland on Oct. 18, 2021.